Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
AUGUSTUS: After ACS or PCI, aspirin gives AFib patients scant benefit
- Author:
- Mitchel L. Zoler, PhD
Adding aspirin to an anticoagulant and P2Y12 inhibitor showed no net benefit, even acutely, suggesting need to target aspirin to highly selected...
News
ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
A study drawing from 1,128 hypertensive, Chinese patients with COVID-19 suggested that those on an ACEI or ARB...
News
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
- Author:
- Mitchel L. Zoler, PhD
Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and...
News
Imaging recommendations issued for COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
An expert panel organized by the Fleischner Society made recommendations on using chest radiography or CT in hospitalized COVID-19 patients.
News
Evidence suggests possible RAS-blocker benefit in COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
Animal findings and physiologic mechanisms suggest RAS system inhibitors may benefit COVID-19 patients,...
News
AHA updates management when CAD and T2DM coincide
- Author:
- Mitchel L. Zoler, PhD
Statement encourages and guides greater involvement by cardiovascular specialists in managing patients with...
News
Radial arteries show CABG survival advantage over saphenous veins
- Author:
- Mitchel L. Zoler, PhD
For the first time, an arterial alternative to saphenous vein grafts produced a survival benefit when used as the second CABG conduit.
News
VOYAGER PAD: Clopidogrel adds no benefit to rivaroxaban plus aspirin after PAD interventions
- Author:
- Mitchel L. Zoler, PhD
Analysis of VOYAGER PAD results showed no benefit with clopidogrel, but patients on three antithrombotics had more bleeding episodes.
News
New lipid-lowering drug class slashes LDL in HoFH patients
- Author:
- Mitchel L. Zoler, PhD
Evinacumab, a broadly active, lipid-lowering drug with a novel mechanism, cut LDL-cholesterol levels by 47% in patients with homozygous familial...
News
Outcomes-based measurement of TAVR program quality goes live
- Author:
- Mitchel L. Zoler, PhD
The ACC and STS team that runs the mandated U.S. national TAVR registry devised and is launching a new metric to measure program quality.
News
Rivaroxaban plus aspirin safely benefits PAD patients after limb revascularization
- Author:
- Mitchel L. Zoler, PhD
The first major treatment trial in PAD patients who underwent lower-limb revascularization showed net clinical...
News
Wuhan data link COVID-19 with myocardial damage
- Author:
- Mitchel L. Zoler, PhD
Findings from 603 COVID-19 patients at two Wuhan hospitals showed a high incidence of myocardial damage that...
News
COVID-19 critical care guideline offers support for frontline clinicians
- Author:
- Mitchel L. Zoler, PhD
The target users of this guideline are frontline clinicians, allied health professionals, and policy makers involved in the care of patients with...
News
Intracranial artery stenting shows promising 1-year results
- Author:
- Mitchel L. Zoler, PhD
LOS ANGELES – Intracranial stenting after stroke received a hit in the 2011 SAMMPRIS results, but new findings revive promise.
News
COVID-19: U.S. cardiology groups reaffirm continued use of RAAS-active drugs
- Author:
- Mitchel L. Zoler, PhD
Experts give ACE inhibitors and ARBs, cornerstones of cardiology therapy, a thumbs up despite a hypothetical adverse COVID-19 effect.